ReviewTherapeutics and clinical risk management2021

Current Opinions on the Clinical Utility of Ravulizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

Carmelo Gurnari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.